Evidence map›Paper›PMID 37391487›Full record

ArticleLeukemia2023

Correction: An MDM2 degrader for treatment of acute leukemias.

Bridget K Marcellino, Xiaobao Yang, H Ümit Kaniskan, Claudia Brady, He Chen, Karie Chen, Xing Qiu, Cara Clementelli, Lauren Herschbein, Zhijun Li and 8 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Bridget K Marcellino *Department of Medicine, Division of Hematology Oncology and Tisch Cancer Institute (TCI), Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Xiaobao Yang *Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Tisch Cancer Institute (TCI) Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, NY, USA.
H Ümit Kaniskan *Mount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Tisch Cancer Institute (TCI) Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, NY, USA.
Claudia BradyDepartment of Medicine, Division of Hematology Oncology and Tisch Cancer Institute (TCI), Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
He ChenMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Tisch Cancer Institute (TCI) Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, NY, USA.
Karie ChenDepartment of Medicine, Division of Hematology Oncology and Tisch Cancer Institute (TCI), Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Xing QiuMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Tisch Cancer Institute (TCI) Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, NY, USA.
Cara ClementelliDepartment of Medicine, Division of Hematology Oncology and Tisch Cancer Institute (TCI), Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Lauren HerschbeinDepartment of Medicine, Division of Hematology Oncology and Tisch Cancer Institute (TCI), Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.ORCID http://orcid.org/0000-0001-8274-6858
Zhijun LiUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Sebastian Elghaity-BeckleyDepartment of Medicine, Division of Hematology Oncology and Tisch Cancer Institute (TCI), Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Joann ArandelaDepartment of Medicine, Division of Hematology Oncology and Tisch Cancer Institute (TCI), Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Brianna KellyDepartment of Medicine, Division of Hematology Oncology and Tisch Cancer Institute (TCI), Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.
Ronald HoffmanDepartment of Medicine, Division of Hematology Oncology and Tisch Cancer Institute (TCI), Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA.ORCID http://orcid.org/0000-0001-6564-6732
Jing LiuMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Tisch Cancer Institute (TCI) Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, NY, USA.
Yue XiongUniversity of North Carolina at Chapel Hill, Chapel Hill, NC, USA. yxiong@email.unc.edu.
Jian JinMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences, Oncological Sciences, and Neuroscience, Tisch Cancer Institute (TCI) Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York, NY, USA. jian.jin@mssm.edu.ORCID http://orcid.org/0000-0002-2387-3862
Alan H ShihDepartment of Medicine, Division of Hematology Oncology and Tisch Cancer Institute (TCI), Icahn School of Medicine at Mount Sinai (ISMMS), New York, NY, USA. alan.shih@mssm.edu.ORCID http://orcid.org/0000-0003-4618-9673

Funding

Tissue BankP01CA108671 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Ronald Hoffman · 2006 to 2026
$82.0M
The Physiological Function and Regulation of INK4 GenesR01CA068377 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MARZLUFF, WILLIAM F. · 1995 to 2021
$6.5M
NCI NIH HHS P01 CA108671NCI NIH HHS R01 CA068377
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37391487
PMCPMC12053532

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.